厄罗替尼单药治疗晚期非小细胞肺癌的疗效和安全性分析

Efficacy and Safety of Erlotinib as Monotherapy for Advanced Non-small Cell Lung Cancer

目的研究厄罗替尼单药治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 50例晚期NSCLC患者接受了厄罗替尼治疗,其中19例进行了表皮生长因子受体基因检测。中位生存期采用Kaplan-Meier方法计算。结果最常见的不良反应为皮疹(96%)和腹泻(32%)。中位生存期为21.8月,95%可信区间(CI)为17.1～26.4月。中位无疾病进展生存期为7.0月,95%CI为3.9～10.1月。19例接受表皮生长因子受体基因检测的患者中,突变型8例、野生型11例。突变型和野生型患者的客观有效率分别为62.5%和9.1%,差异具有显著性(χ2=6.631,P=0.036);无疾病进展生存期分别为16.330(95%CI2.803～29.857)和5.570月(95%CI2.441～8.699),两者差异具有显著性(χ2=8.799,P=0.003)。结论晚期NSCLC患者接受厄罗替尼治疗安全有效。

Objective To explore the efficacy and safety of erlotinib monotherapy for advanced non-small cell lung cancer (NSCLC).Methods Totally 50 patients with advanced NSCLC received oral erlotinib 150 mg/d treatment,and tumor specimen in 19 patients were collected for epidermal growth factor receptor (EGFR) gene mutation tests.Median survival (MS) was calculated using the Kaplan-Meier method.Results The most common adverse events (AEs) were skin rash (96%) and diarrhea (32%).The overall survival(OS) of all patient...